Published in final edited form as:

J Med Chem. 2012 September 13; 55(17): 7546–7559. doi:10.1021/jm3005543.

Discovery of a novel non-iminosugar acid alpha glucosidase chaperone series

Jingbo Xiao¹, Wendy Westbroek², Omid Motabar¹, Wendy A. Lea¹, Xin Hu¹, Arash Velayati², Wei Zheng¹, Noel Southall¹, Ann Marie Gustafson², Ehud Goldin², Ellen Sidransky², Ke Liu¹, Anton Simeonov¹, Rafael J. Tamargo², Antonia Ribes³, Leslie Matalonga³, Marc Ferrer¹, and Juan J. Marugan^{1,*}

¹NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850

²Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35 Rm1A213, 35 Convent Drive, Bethesda, Maryland 20892

³Enfermedades Metabólicas Hereditarias, Institut de Bioquímica Clínica, Servicio de Bioquímica y Genética Molecular, Hospital Clínic y Provincial de Barcelona, Barcelona, Spain

Abstract

Pompe disease is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the lysosomal enzyme acid alpha glucosidase (GAA). Many disease-causing mutated GAA retain enzymatic activity, but are not translocated from endoplasmic reticulum (ER) to lysosomes. Enzyme replacement therapy (ERT) is the only treatment for Pompe disease, but remains expensive, inconvenient and does not reverse all disease manifestations. It was postulated that small molecules which aid in protein folding and translocation to lysosomes could provide an alternate to ERT. Previously, several iminosugars have been proposed as small-molecule chaperones for specific LSDs. Here we identified a novel series of non-iminosugar chaperones for GAA. These moderate GAA inhibitors are shown to bind and thermo-stabilize GAA, and increase GAA translocation to lysosomes in both wild-type and Pompe fibroblasts. AMDE and physical properties studies indicate that this series is a promising lead for further pharmacokinetic evaluation and testing in Pompe disease models.

INTRODUCTION

LSDs represent over 50 different rare diseases and result from mutations in lysosomal enzymes. Phenotypically, cells affected by LSDs are characterized by lysosomal enlargement due to accumulation of disease-specific substrates.¹ Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is an autosomal recessive LSD caused by mutations in the lysosomal enzyme GAA² with a frequency of approximately 1 in every 40,000 births.³ Disease progression is variable and clinical symptoms can include progressive muscle weakness and loss of motor, respiratory, and

*To whom correspondence should be addressed: NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850. Phone: 301-217-9198. Fax: 301-217-5736. maruganj@mail.nih.gov.

SUPPORTING INFORMATION

The data from the primary screening as well as all the inhibitory curves of every final compound in all the described assays are available on line (PubChem AID's: 1466, 2101, 2107, 2108, 2109, 2100, 2110, 2111, 2112, 2113, 2115 and 2641). Additional data of our translocation experiment and selectivity assays for compound **1** are available free of charge at <http://pubs.acs.org>.

cardiac function. In most patients, premature death occurs due to respiratory complications. GAA hydrolyzes the terminal α -1,4-glucosidic linkages of glycogen in the lysosome. Mutations in GAA result in lysosomal enlargement due to glycogen accumulation, especially in cardiac and skeletal muscle.² There are more than 100 different disease-causing GAA mutations identified in Pompe patients affecting enzyme expression, conformation, and activity.⁴ As in other LSDs, many of the mutant proteins retain residual enzyme activity *in vitro* but are unable to function because of impaired translocation from the ER to the lysosome. Consequently, mutant enzyme accumulates in the ER, is ubiquitinated and will eventually undergo ERAD. Currently, the only FDA-approved treatment for children with this disease is ERT with recombinant human GAA (alglucosidase alfa), a recombinant human GAA produced in Chinese hamster ovary cells.⁵ Although recombinant human GAA (alglucosidase alfa) is proven to be clinically efficacious, treatment is not optimal. Many patients test positive for IgG antibodies to GAA which reduces the clinical utility,⁶ its intravenous administration is inconvenient, the cost can be over \$300,000/year and adverse side effects can occur.⁷ This reinforces the need for developing alternative treatments for Pompe disease.

Protein translocation from ER to the site of action is a dynamic process involving distinct transporters that interact with low energy conformations of the protein, a thermodynamically driven process and kinetically accelerated by ER chaperones.⁸ Treatment with appropriate small-molecule chaperones could kinetically accelerate the protein folding process and promote translocation of mutant enzyme.⁹ For GAA, improving trafficking of the mutant protein between the ER and the lysosome by small molecule chaperone treatment might reduce glycogen storage and lysosome size.¹⁰ Iminosugars are well-known small molecule inhibitors of glycosidases¹¹ that bind to the active site of the enzyme, mimicking the transition state of the glycolytic hydrolysis (Figure 1).¹² This accelerates the folding process, and therefore iminosugar inhibitors have been proposed for the treatment of various LSDs.¹³ Although the chaperone activity of iminosugars is established, their use has several pitfalls. They exhibit poor selectivity among several glycosidases and need to be actively transport and therefore differences in bioavailability and body distribution among patients must be considered. Additionally due to their inhibitory activity the therapeutic window between translocation and enzyme function efficacy is small, and pharmacokinetics must be taken into consideration for modulation of the concentration at the site of action. Currently all small-molecule GAA chaperones reported in the literature are iminosugar inhibitors with 1-deoxynojirimycin (DNJ) being at the moment evaluated in a phase II clinical trial as a therapy for Pompe disease by Amicus Therapeutics Inc.¹⁴ Other than DNJ and NB-DNJ, no other reported inhibitors have been shown to have GAA chaperone capacity or utility in the treatment of Pompe disease.¹⁰

Our group has developed several new screening methodologies to identify novel non-iminosugar series impacting enzymatic activity in LSD assays. We have focused on testing enzymes in a context as native as possible, including measuring the hydrolytic capacity of GAA in tissue homogenate.¹⁵ Many isolated glucosidases require allosteric activation to be functional,¹⁶ so we attempted to avoid using purified enzyme preparations, which depend upon the use of detergents to induce the active conformation and catalysis the activity of the enzyme. While it is common to find compounds that can inhibit isolated enzymes, these molecules are often inactive in cellular lysates. This is likely due to conformational differences between detergent-induced enzymatic systems and the physiological enzyme in cells, or problems with non-specific protein binding. Another limitation of reconstituted assays is the inability to detect enzyme activators, presumably because the detergent used in reconstituted assays over-activates the enzyme in a non-physiological way. One way to overcome these problems is to screen the enzyme directly from tissue homogenate using a probe specific for GAA activity, such as 4-methylumbelliferyl α -D-glucopyranoside.¹⁵

Upon hydrolysis, the blue fluorescent dye 4-methylumbelliferone is liberated, producing a fluorescent emission at 440 nm when excited at 370 nm. To control for auto-fluorescence, we also used a second substrate, resorufin α -D-glucopyranoside, which liberates the red dye resorufin at an emission wavelength of 590 nm when excited at 530 nm (Figure 2).

In this study, we present the first non-iminosugar inhibitor chaperone series for GAA identified screening a novel method using tissue homogenate instead of purified enzyme preparations. This series inhibited GAA activity in both tissue homogenate and purified enzyme assays and showed translocation capacity to the lysosomal compartment in wild type and Pompe fibroblasts in a cell-based immunostaining assay.¹⁷ This promising series merits further evaluation as a potential new therapy for Pompe disease.

RESULTS AND DISCUSSION

Hit from qHTS

244,319 compounds from the NIH Molecular Libraries-Small Molecule Repository (ML-SMR) were screened.¹⁸ The Z' across the entire screen was 0.82 ± 0.04 . Only one non-iminosugar inhibitor series, represented by compound **1**, was identified based on selectivity against related enzymes including alpha galactosidase and glucocerebrosidase (data in supporting information). In addition, compound **1** displayed similar activity in both purified GAA and tissue homogenate assays, and it was not auto-fluorescent as determined by spectral profiling (Figure 3). The inhibitory activity of compound **1** was further evaluated using purified enzyme with its native substrate, glycogen. Glycogen from bovine liver was used as the substrate and recombinant human GAA as the enzyme preparation. Upon hydrolysis of the substrate, the glucose product could be detected using the Amplex Red Glucose Oxidase assay kit, and the product of this reaction was detected in a fluorescence plate reader. Compound **1** had a potency of 330 nM in this assay (data not shown), consistent with its activity in the primary screen using pro-fluorescent substrates.

In addition to the previously described secondary assays, we tested the ability of compound **1** to protect GAA activity upon exposure to thermal defunctionalization conditions (Figure 4). Briefly, hydrolytic enzymes lose their catalytic activity over time when exposed to elevated temperatures below their melting point due to progressive denaturation and/or aggregation of the protein from solution. Incubating GAA at 66 °C for 60 minutes reduces the enzyme activity by about 75%. Small molecules with the capacity to bind and stabilize the enzyme are expected to prevent this loss of activity. Moreover, compounds able to prevent thermal destabilization usually also promote proper cellular folding and translocation, and therefore can be good chaperones. Figure 4 clearly demonstrates that compound **1** can thermo-stabilize GAA.

Chemistry and SAR Studies

These data encouraged us to embark on structural modifications to provide a better understanding of SAR for this series. Schemes 1 and 2 showed the general methodology used for the synthesis of analogs with modifications in several regions of the molecule. Direct chlorosulfonylation of 2-indolinone at the 5-position,¹⁹ followed by piperazine or substituted aniline displacements, yielded analogs **1–15** and **34** with modifications on the aromatic ring attached to the piperazine moiety. Analog **15** with *para*-methyl ester substituent was readily converted to the corresponding carboxylic acid or methyl alcohol analogs **16** and **17** via acidic hydrolysis or DIBAL reduction. Alternatively, reaction of 1-(4-(piperazin-1-yl)phenyl)ethanone with a variety of sulfonyl chlorides in the presence of a suitable base such as triethylamine gave analogs with modifications at the indolinone ring (analog **18–31**). Furthermore, reaction of 1-(4-(piperazin-1-yl)phenyl)ethanone with

carboxylic acid under EDC coupling conditions resulted in analogs **32** and **33** with replacement of sulfonamide moiety with a carbonamide (Scheme 2).

Each synthesized analog was assayed for GAA inhibition using the tissue homogenate with two different pro-fluorescent substrates, a blue shifted dye substrate that was used in the primary screen and a red shifted dye substrate. The inhibitory activity of the analogs was consistent in assays with both the blue and red-shifted dye substrates. Tables 1 to 3 demonstrate the SAR of synthesized analogs with modifications at three areas of the hit compound **1**. Table 1 shows that a broad range of substituents were tolerated within the aromatic ring attached to the piperazine portion of the molecule, including *para*-hydroxyl (analog **5**, $IC_{50} = 1.88 \mu M$), *para*-cyano (analog **7**, $IC_{50} = 2.91 \mu M$), *para*-nitro (analog **8**, $IC_{50} = 3.66 \mu M$), *para*-formaldehyde (analog **14**, $IC_{50} = 3.66 \mu M$) and *para*-carboxylic acid (analog **16**, $IC_{50} = 1.30 \mu M$) functional groups. However, *para*-methoxy, *para*-methyl ester and *para*-methyl alcohol derivatives showed a 25–50 fold loss of activity (analog **4**, $IC_{50} = 23.69 \mu M$; analog **15**, $IC_{50} = 25.90 \mu M$; analog **17**, $IC_{50} = 12.98 \mu M$). Other functional groups, like halo (analog **9–11**), methyl (analog **6**) and trifluoromethyl (analog **12** and **13**), were either inactive or had much less activity. Surprisingly, elimination of the phenyl ring, while keeping the methylketone moiety, resulted in derivative **3** with decent activity ($IC_{50} = 11.87 \mu M$), while further elimination of the methylketone group gave an inactive analog **2**. These data indicates that the electronic nature of phenyl substituents has minor effect on the inhibitory activity, and that an oxygen or nitrogen at the *para*-position of the phenyl group might be involved in hydrogen bonding interactions enhancing activity.

The SAR for the indolinone group was found to be very narrow (Table 2). Most modifications such as the introduction of more heteroatoms (analog **18–21**, **24**, **31**), increasing the size of the aliphatic portion of the indolin-2-one (analog **25** and **26**), or elimination of the aliphatic ring to obtain the acetamide derivatives (analog **27–30**) all yielded inactive compounds. The only modification on this part of the molecule that did not have significant impact on activity was the introduction of a chlorine substituent on the 6-position of the indolinone ring (analog **22**, $IC_{50} = 1.63 \mu M$). The 3,3-dichloro substituted indolinone analog (**23**, $IC_{50} = 32.61 \mu M$) was also active, but much less potent.

Table 3 demonstrates the effect of replacing the sulfonamide with a carbonamide (analog **32** and **33**) or a reversed phenyl and piperazine ring analog (**34**). All three analogs were found to be inactive. Therefore, the sulfonamide moiety also contributed significantly to the inhibitory activity of this chemical scaffold.

Biological Evaluation

With the SAR assessment established for this scaffold, we evaluated the ability of selected analogs with reasonable potency to stabilize GAA against thermal defunctionalization. As shown in Figure 5, in the presence of tested GAA inhibitors, GAA was able to maintain its function compared to DMSO control. The stabilization observed correlated directly with the inhibitory activity of the compounds in the inhibition assay. In other words, the best inhibitors were the best stabilizers; importantly, analog **22** showed a strong ability to stabilize GAA against thermal denaturation, similar to the hit compound **1**. These data demonstrated that these inhibitors could stabilize the preferred 3 dimensional conformation of GAA, validating their potential value as small-molecule chaperones.

Another way to test the capacity of a chemical series to stabilize a protein is to measure the impact of the compounds on the melting temperature (T_m) of the protein. For some chemical series, there is a direct correlation between the binding affinities of the compounds toward a protein and their capacity to increase the protein's T_m .²⁰ Analogs **1** and **22** demonstrated a concentration dependent ability to raise the T_m of GAA (Figure 6A). To further evaluate the

binding interaction between these two analogs and GAA, we also measured the corresponding binding affinity (K_d) by microscale thermophoresis (MST).²¹ A direct interaction between small molecules and GAA was indeed observed for both analogs **1** and **22** (Figure 6B). Due to solubility limits, concentrations at above 250 μ M could not be tested (thus saturation binding could not be determined for analog **22**). Nevertheless, an apparent dissociation constant (K_d) for analogs **1** and **22** was observed to be in a range of 20–60 μ M, with analog **1** showing a stronger binding than analog **22**. These calculated K_d 's are 20 to 40 times higher than their reported IC_{50} 's possibly due to differences in affinity as a consequence of labeling the enzyme and the impact in enzymatic conformation and in compound solubility of isolated-tissue homogenated conditions.

The encouraging results from the GAA thermo-stabilization and direct binding experiments led us to explore whether this chemical series had an impact on GAA translocation. Most LSDs are biochemically diagnosed by measuring the specific activity of the hydrolase on patient cell samples. However, Pompe-associated glycogen accumulation primarily impacts cardiac and skeletal muscle and these tissues are often not available. Therefore, in many LSDs, including Pompe disease, the enzyme activity is analyzed on skin fibroblasts. Thus, we decided to evaluate our inhibitors in fibroblasts. In contrast to other LSDs, there is no common mutation in Pompe disease, therefore we initially chose wild type human fibroblasts to evaluate the chaperone and translocation capacity of analogs **1** and **22**. First we tested the specificity of the mouse monoclonal anti-GAA antibody. On western blot, the antibody recognized the GAA protein (kDa) in protein lysate from human embryonic kidney (HEK) cells electroporated with a pCMV6XL6 plasmid containing the GAA cDNA (Acc No. NM_000152.2); non-electroporated HEK cells and wild type fibroblast protein lysates (Figure 7A) did not show a GAA specific signal. However, wild type fibroblasts express low levels of GAA. Next, we performed a cell-based translocation assay for GAA. In DMSO-treated primary wild type fibroblasts, GAA staining was observed in about 15 % of the cells, and the GAA stain (green) co-localized with the lysosomal marker cathepsin D (red) (Figure 7B, a). Wild type fibroblasts stained with secondary antibodies Alexa-488 and Alexa-555 showed no signal at the same laser settings (Figure 7B, b), indicating that the green signal from the GAA antibody was specific and not due Alexa-488 secondary antibody background. It should also be noted that GAA staining and translocation to lysosomes in fibroblasts significantly decreased with increasing cell passage number; wild type fibroblast with passage number 7 showed GAA staining in lysosomes in about 15 % of the cells, while passage 8 cells showed translocation in 10 % of the cells (data not shown). It is known that inhibitory chaperones have a small therapeutic window in which the molecule displays translocation without complete elimination of the enzymatic activity. For this reason good chaperone molecules should be weak inhibitors, allowing its displacement in the lysosome by the natural substrate. *In vivo*, this is resolved by titrating the optimal dose for maximal activity. In cell based assays, this is addressed by varying the compound concentration and length of exposure.

Compound **1** was toxic for both wild type and Pompe fibroblasts (passage number 7) at 10, 15, and 20 μ M after a 6-day treatment, suggesting that this molecule has too much inhibitory capacity, resulting in total suppression of enzyme activity. Moreover, 6-day ablation of GAA activity in fibroblasts induces cell death. After a 5-day of treatment, both wild type cells and Pompe fibroblast were viable but did not show an increase of GAA translocation upon exposure to 1 or 5 μ M of compound **1**, indicating that this compound might have a poor therapeutic window or that our GAA antibody does not good enough sensibility to detect low changes in this enzyme. In contrast, a 6-day treatment of wild type fibroblasts (passage number 7) with 15 μ M (Figure 7B, c) or 5 μ M (Figure 7B, d) of compound **22** significantly up-regulated the translocation of GAA to the lysosomes. About 40 % of the cells showed translocation of GAA with treatment at 15 μ M concentration and

30 % with 5 μ M. Pompe fibroblasts treated with DMSO showed no GAA signal (green) in lysosomes (Figure 7C, a). Six days of treatment with compound **22** in Pompe fibroblasts resulted in cell toxicity, probably due to excessive inhibition of the enzyme. Reducing the time of exposure provided better results. Thus, a 5-day treatment with 5 μ M of compound **22** showed translocation in all three Pompe cell lines (Figure 7C, b; data only shown for the F2845 Pompe cell line) while treatment with 1 μ M did not induce translocation, indicating that analog **22** is able to increase the translocation of GAA in both wild type and Pompe cell lines and showing that this chemical series has potential as a GAA chaperone for the treatment of Pompe disease. It should be noted that the concentration necessary for reasonable translocation *in vivo* could be considerably lower due to the high expression of GAA in affected tissues.

Last, we also measure the elevation of GAA specific activity upon treatment. Figure 8 discloses that upon five days of treatment, inhibitors **1** and **22** are able to increase GAA activity of wt and one of our mutant cell lines, confirming the results observed in our translocation experiment. Importantly, increments in activity can be observed at lower concentrations of their described IC₅₀'s indicating a potentially good therapeutic window.

***In vitro* ADME Properties**

Five selected analogs with IC₅₀ less than 3.0 μ M in the GAA inhibitory assay using blue dye were profiled for PBS aqueous solubility, mouse liver microsomal stability and cell permeability in Caco-2 cells (Table 4). The aqueous solubility of the hit compound **1** in PBS buffer was 10 fold above its IC₅₀ value. The solubility was significantly increased for analogs with polar functionalities, such as hydroxyl or carboxylic acid groups. Interestingly, the introduction of a chlorine atom at the 6-position of indolinone moiety also enhanced its aqueous buffer solubility. The microsomal stability tests disclosed that all five analogs showed excellent metabolic stability in mouse liver microsomes. In addition, this metabolic transformation was NADPH-dependent (data not shown), indicating that the major metabolic process occurs through cytochrome P450-dependent oxidation. Moreover, the data in Table 5 indicates that hit compound **1** had very good cell permeability, with reasonable efflux (ratio = 1.9, [B3A/A3B]). The chloro analog **22** has even better permeability with a reduced efflux ratio (0.57). As expected, the carboxylic acid analog **16** displayed very poor cell permeability. Overall, analog **22** demonstrated improved aqueous solubility, excellent microsomal stability, and cell permeability in addition to its capacity of increasing GAA translocation and activity in both wild type and Pompe cells. Therefore, analog **22** is a promising lead candidate for further development for the treatment of Pompe disease.

CONCLUSIONS

In summary, we present the first non-iminosugar GAA chaperone series identified from a qHTS campaign. This series of compounds inhibit GAA activity in both tissue homogenate and purified enzyme assays using native or artificial substrates. In addition, these inhibitors are highly selective against the related lysosomal hydrolases alpha galactosidase and glucocerebrosidase. SAR studies produced several optimized compounds that are able to stabilize GAA in thermo-functional and thermal denaturation assays. Furthermore, MST studies display that these molecules are indeed binders of GAA with their apparent K_ds tracking well with their inhibitory activities. Improved compounds display good physical and ADME properties while maintaining GAA inhibitory activity. Importantly optimized analog **22** showed an appropriate balance between inhibitory and translocation capacity in both wild type and Pompe cells, making it a promising lead for further pharmacological development.

EXPERIMENTAL SECTION

General Chemistry Methods

All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Anhydrous solvents such as dichloromethane, *N,N*-dimethylformamide (DMF), acetonitrile, methanol and triethylamine were purchased from Sigma-Aldrich (St. Louis, MO). Preparative purification was performed on a Waters semi-preparative HPLC system (Waters Corp., Milford, MA). The column used was a Phenomenex Luna C₁₈ (5 micron, 30 × 75 mm; Phenomenex, Inc., Torrance, CA) at a flow rate of 45.0 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10% to 50% acetonitrile over 8 minutes was used during the purification. Fraction collection was triggered by UV detection at 220 nm. Analytical analysis was performed on an Agilent LC/MS (Agilent Technologies, Santa Clara, CA) using a method of a 7-minute gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) with an 8-minute run time at a flow rate of 1.0 mL/min. A Phenomenex Luna C₁₈ column (3 micron, 3 × 75 mm) was used at a temperature of 50 °C. Purity determination was performed using an Agilent diode array detector and all of the analogs tested in the biological assays have a purity of greater than 95%. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode. ¹H NMR spectra were recorded on Varian 400 MHz spectrometers (Agilent Technologies, Santa Clara, CA). Chemical shifts are reported in ppm with undeuterated solvent (DMSO-*d*₆ at 2.49 ppm) as internal standard for DMSO-*d*₆ solutions. High resolution mass spectrometry was recorded on Agilent 6210 Time-of-Flight (TOF) LC/MS system. Confirmation of molecular formula was accomplished using electrospray ionization in the positive mode with the Agilent Masshunter software (Version B.02).

General Protocol A—A solution of 1-substituted piperazine (0.216 mmol), triethylamine (0.120 mL, 0.863 mmol) in DMF (1.50 mL) was treated at room temperature with 2-oxoindoline-5-sulfonyl chloride (50.0 mg, 0.216 mmol). The reaction mixture was stirred overnight at room temperature. The crude mixture was filtered and purified by preparative HPLC to give the final product.

General Protocol B—A solution of 1-(4-(piperazin-1-yl)phenyl)ethanone (71.5 mg, 0.350 mmol), triethylamine (0.098 mL, 0.700 mmol) in DMF (2.00 mL) was treated at room temperature with sulfonyl chloride (0.350 mmol). The reaction mixture was stirred overnight at room temperature. The crude mixture was filtered and purified by preparative HPLC to give the final product.

General Protocol C—A solution of 1-(4-(piperazin-1-yl)phenyl)ethanone (71.5 mg, 0.350 mmol), triethylamine (0.098 mL, 0.700 mmol) in DMF (2.00 mL) was treated at room temperature with sulfonyl chloride (0.350 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was poured into water and the solid fraction was crushed out. The solid fraction was filtered and dried to give the final product.

General Protocol D—A solution of 1-(4-(piperazin-1-yl)phenyl)ethanone (0.086 g, 0.420 mmol), carboxylic acid (0.350 mmol) in DMF (2.00 mL) was treated at room temperature with EDC (0.067 g, 0.350 mmol) and DMAP (0.043 g, 0.350 mmol). The reaction mixture was stirred overnight at room temperature. The crude mixture was filtered and purified by preparative HPLC to the final product.

2-Oxoindoline-5-sulfonyl chloride—Indolin-2-one (5.00 g, 37.6 mmol) was added at 30 °C to hypochlorous sulfonic anhydride (10.2 mL, 153 mmol) in portions. The reaction mixture was stirred at room temperature for 1.5 h and heated to 70 °C for 1 h. The reaction was slowly quenched with water, the light pink solid precipitation was filtered and dried to give 5.33 g (yield 61%) of product which was used in the next reaction without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.40 (s, 1 H), 7.31 – 7.46 (m, 2 H), 6.71 (dd, *J*=7.8, 0.6 Hz, 1 H), 3.45 (s, 2 H).

5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one (1)—A solution of 1-(4-(piperazin-1-yl)phenyl)ethanone (485 mg, 2.37 mmol), triethylamine (0.602 mL, 4.32 mmol) in DMF (10.0 mL) was treated at room temperature with 2-oxoindoline-5-sulfonyl chloride (500 mg, 2.16 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was poured into water and the solid fraction was crushed out, filtered, and dried to give 658 mg (yield 76%) of product as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.83 (s, 1 H), 7.67 – 7.95 (m, 2 H), 7.47 – 7.71 (m, 2 H), 7.01 (d, *J*=8.2 Hz, 1 H), 6.88 – 6.97 (m, 2 H), 3.59 (s, 2 H), 3.38 – 3.50 (m, 4 H), 2.92 – 3.05 (m, 4 H), 2.43 (s, 3 H). LCMS RT = 4.46 min, *m/z* 400.1 [M+H⁺]; HRMS (ESI) *m/z* calcd. for C₂₀H₂₂N₃O₄S [M+H⁺] 400.1326, found 400.1330.

5-(Piperazin-1-ylsulfonyl)indolin-2-one (2)—A solution of piperazine (1.67 g, 19.4 mmol), triethylamine (2.71 mL, 19.4 mmol) in DMF (10.0 mL) was treated at 0 °C with 2-oxoindoline-5-sulfonyl chloride (1.50 g, 6.48 mmol) in DMF (10.0 mL). The reaction mixture was stirred overnight at room temperature. DMF was removed and dichloromethane was added to precipitate out the product. The solid fraction was filtered and washed with dichloromethane to give the final product as a brown solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.89 (s, 1 H), 8.47 (br. s., 1 H), 7.51 – 7.74 (m, 2 H), 6.97 – 7.09 (m, 1 H), 3.62 (s, 2 H), 3.11 – 3.25 (m, 4 H), 2.99 – 3.11 (m, 4 H); LCMS RT = 2.66 min, *m/z* 282.1 [M+H⁺]; HRMS (ESI) *m/z* calcd. for C₁₂H₁₆N₃O₃S [M+H⁺] 282.0907, found 282.0912.

5-(4-Acetyl piperazin-1-ylsulfonyl)indolin-2-one (3)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.79 (s, 1 H), 7.35 – 7.60 (m, 2 H), 6.96 (d, *J*=8.2 Hz, 1 H), 3.55 (s, 2 H), 3.46 (q, *J*=5.2 Hz, 4 H), 2.80 (ddd, *J*=19.8, 5.2, 4.9 Hz, 4 H), 1.89 (s, 3 H); LCMS RT = 3.36 min, *m/z* 346.1 [M+Na⁺]; HRMS (ESI) *m/z* calcd. for C₁₄H₁₈N₃O₄S [M+H⁺] 324.1013, found 324.1019.

5-(4-(4-Methoxyphenyl)piperazin-1-ylsulfonyl)indolin-2-one (4)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.84 (s, 1 H), 7.48 – 7.71 (m, 2 H), 7.02 (d, *J*=8.2 Hz, 1 H), 6.70 – 6.94 (m, 4 H), 3.66 (s, 3 H), 3.61 (s, 2 H), 3.02 – 3.11 (m, 4 H), 2.91 – 3.02 (m, 4 H); LCMS RT = 4.45 min, *m/z* 388.1 [M+Na⁺]; HRMS (ESI) *m/z* calcd. for C₁₉H₂₂N₃O₄S [M+H⁺] 388.1326, found 388.1330.

5-(4-(4-Hydroxyphenyl)piperazin-1-ylsulfonyl)indolin-2-one (5)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.80 (s, 1 H), 8.88 (br. s., 1 H), 7.42 – 7.68 (m, 2 H), 6.98 (d, *J*=8.0 Hz, 1 H), 6.74 (d, *J*=7.6 Hz, 2 H), 6.45 – 6.67 (m, 2 H), 3.57 (s, 2 H), 2.82 – 3.09 (m, 8 H); LCMS RT = 3.49 min, *m/z* 374.1 [M+H⁺]; HRMS (ESI) *m/z* calcd. for C₁₈H₂₀N₃O₄S [M+H⁺] 374.1169, found 374.1173.

5-(4-*p*-Tolylpiperazin-1-ylsulfonyl)indolin-2-one (6)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.82 (s, 1 H), 7.45 – 7.66 (m, 2 H), 7.00 (dd, *J*=8.0, 5.9 Hz, 3 H), 6.74 – 6.85 (m, 2 H), 3.59 (s, 2 H),

3.06 – 3.21 (m, 4 H), 2.89 – 3.06 (m, 4 H), 2.17 (s, 3 H); LCMS RT = 5.08 min, m/z 372.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₂N₃O₃S [M+H⁺] 372.1376, found 372.1380.

4-(4-(2-Oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzonitrile (7)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.79 (s, 1 H), 7.40 – 7.66 (m, 4 H), 6.82 – 7.13 (m, 3 H), 3.54 (s, 2 H), 3.36 – 3.43 (m, 4 H), 2.88 – 2.97 (m, 4 H); LCMS RT = 4.89 min, m/z 383.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₁₉N₄O₃S [M+H⁺] 383.1172, found 383.1173.

5-(4-(4-Nitrophenyl)piperazin-1-ylsulfonyl)indolin-2-one (8)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.79 (s, 1 H), 8.00 (d, *J*=9.6 Hz, 2 H), 7.47 – 7.64 (m, 2 H), 6.88 – 7.04 (m, 3 H), 3.45 – 3.68 (m, 6 H), 2.85 – 3.01 (m, 4 H); LCMS RT = 5.02 min, m/z 425.1 [M+Na⁺]; HRMS (ESI) m/z calcd. for C₁₈H₁₉N₄O₅S [M+H⁺] 403.1071, found 403.1071.

5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)indolin-2-one (9)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.80 (s, 1 H), 7.41 – 7.69 (m, 2 H), 6.93 – 7.08 (m, 3 H), 6.77 – 6.92 (m, 2 H), 3.56 (s, 2 H), 3.05 – 3.16 (m, 4 H), 2.87 – 3.00 (m, 4 H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ ppm –126.55 – 123.72 (m); LCMS RT = 5.15 min, m/z 376.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₈H₁₉FN₃O₃S [M+H⁺] 376.1126, found 376.1138.

5-(4-(4-Chlorophenyl)piperazin-1-ylsulfonyl)indolin-2-one (10)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.82 (s, 1 H), 7.49 – 7.74 (m, 2 H), 7.13 – 7.31 (m, 2 H), 7.01 (d, *J*=8.2 Hz, 1 H), 6.78 – 6.96 (m, 2 H), 3.59 (s, 2 H), 3.13 – 3.24 (m, 4 H), 2.87 – 3.03 (m, 4 H); LCMS RT = 5.57 min, m/z 392.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₈H₁₉ClN₃O₃S [M+H⁺] 392.0830, found 392.0842.

5-(4-(4-Bromophenyl)piperazin-1-ylsulfonyl)indolin-2-one (11)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.80 (s, 1 H), 7.48 – 7.72 (m, 2 H), 7.19 – 7.37 (m, 2 H), 6.98 (d, *J*=8.2 Hz, 1 H), 6.77 – 6.87 (m, 2 H), 3.56 (s, 2 H), 3.10 – 3.21 (m, 4 H), 2.88 – 2.98 (m, 4 H); LCMS RT = 5.67 min, m/z 436.0 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₈H₁₉BrN₃O₃S [M+H⁺] 436.0325, found 436.0338.

5-(4-(4-(Trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indolin-2-one (12)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.82 (s, 1 H), 7.52 – 7.68 (m, 2 H), 7.48 (d, *J*=8.6 Hz, 2 H), 6.76 – 7.13 (m, 3 H), 3.58 (s, 2 H), 3.33 – 3.42 (m, 4 H), 2.93 – 3.03 (m, 4 H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ ppm –59.64 (s); LCMS RT = 5.78 min, m/z 426.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₁₉F₃N₃O₃S [M+H⁺] 426.1094, found 426.1101.

5-(4-(3-(Trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indolin-2-one (13)—The title compound was prepared according to general protocol A. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.83 (s, 1 H), 7.50 – 7.73 (m, 2 H), 7.40 (t, *J*=7.9 Hz, 1 H), 7.11 – 7.22 (m, 2 H), 7.08 (d, *J*=8.4 Hz, 1 H), 7.01 (d, *J*=8.0 Hz, 1 H), 3.59 (s, 2 H), 3.25 – 3.31 (m, 4 H), 2.94 – 3.04 (m, 3 H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ ppm –61.14 (s); LCMS RT = 5.78 min, m/z 426.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₁₉F₃N₃O₃S [M+H⁺] 426.1094, found 426.1104.

4-(4-(2-Oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzaldehyde (14)—A solution of 4-(piperazin-1-yl)benzaldehyde, TFA salt (58.0 mg, 0.139 mmol), and triethylamine (0.039 mL, 0.277 mmol) in dichloromethane (2.00 mL) was treated at room temperature with 2-oxoindoline-5-sulfonyl chloride (32.1 mg, 0.139 mmol). The reaction mixture was stirred for 3 h at room temperature. The solid was filtered and dried to a yellow solid product. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.79 (s, 1 H), 9.67 (s, 1 H), 7.60 – 7.72 (m, 2 H), 7.49 – 7.61 (m, 2 H), 6.90 – 7.04 (m, 3 H), 3.55 (s, 2 H), 3.37 – 3.50 (m, 4 H), 2.85 – 2.98 (m, 4 H); LCMS RT = 4.55 min, m/z 386.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₀N₃O₄S [M+H⁺] 386.1169, found 386.1169.

Methyl 4-(4-(2-oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzoate (15)—A solution of methyl 4-(piperazin-1-yl)benzoate (0.687 g, 3.12 mmol), triethylamine (0.870 mL, 6.24 mmol) in dichloromethane (15.0 mL) was treated at room temperature with 2-oxoindoline-5-sulfonyl chloride (0.723 g, 3.12 mmol). The reaction mixture was stirred overnight at room temperature. The yellow solid was filtered and dried to the final product. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.80 (s, 1 H), 7.66 – 7.82 (m, 2 H), 7.46 – 7.63 (m, 2 H), 6.79 – 7.09 (m, 3 H), 3.72 (s, 3 H), 3.55 (s, 2 H), 3.32 – 3.45 (m, 4 H), 2.85 – 3.05 (m, 4 H); LCMS RT = 5.14 min, m/z 416.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₂N₃O₅S [M+H⁺] 416.1275, found 416.1282.

4-(4-(2-Oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzoic acid (16)—A suspension of methyl 4-(4-(2-oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzoate (**15**) (240 mg, 0.578 mmol) in 6.0 N HCl (75.0 mL) was refluxed for 1 h. The reaction mixture was concentrated and purified by preparative HPLC to the final product. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.25 (br. s., 1 H), 10.80 (br. s., 1 H), 7.63 – 7.79 (m, 2 H), 7.38 – 7.63 (m, 2 H), 6.70 – 7.08 (m, 3 H), 3.56 (s, 2 H), 3.32 – 3.43 (m, 4 H), 2.84 – 3.05 (m, 4 H); LCMS RT = 4.46 min, m/z 402.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₀N₃O₅S [M+H⁺] 402.1118, found 402.1126.

5-(4-(4-(Hydroxymethyl)phenyl)piperazin-1-ylsulfonyl)indolin-2-one (17)—DIBAL (0.325 mL, 1.0 M in THF, 0.325 mmol) was added drop wise to a solution of methyl 4-(4-(2-oxoindolin-5-ylsulfonyl)piperazin-1-yl)benzoate (**15**) (45.0 mg, 0.108 mmol) in THF (5.00 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min. The reaction was quenched by addition of methanol, concentrated as a yellow oil which was purified by preparative HPLC to the final product. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.80 (s, 1 H), 7.48 – 7.72 (m, 2 H), 7.10 (d, *J*=8.8 Hz, 2 H), 6.98 (d, *J*=8.2 Hz, 1 H), 6.74 – 6.86 (m, 2 H), 4.32 (s, 2 H), 3.57 (s, 2 H), 3.05 – 3.22 (m, 4 H), 2.88 – 3.04 (m, 4 H); LCMS RT = 4.06 min, m/z 388.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₂N₃O₄S [M+H⁺] 388.1326, found 388.1330.

5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-1H-benzo[d]imidazol-2(3H)-one (18)—The title compound was prepared according to general protocol B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 11.15 (d, *J*=1.2 Hz, 1 H), 10.99 (s, 1 H), 7.59 – 7.87 (m, 2 H), 7.33 (dd, *J*=8.2, 1.8 Hz, 1 H), 7.04 – 7.22 (m, 2 H), 6.79 – 6.97 (m, 2 H), 3.33 – 3.51 (m, 4 H), 2.84 – 3.03 (m, 4 H), 2.39 (s, 3 H); LCMS RT = 4.40 min, m/z 401.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₁N₄O₄S [M+H⁺] 401.1278, found 401.1286.

5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one (19)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.65 – 7.78 (m, 2 H), 7.40 – 7.54 (m, 2 H), 7.34 (d, *J*=8.6 Hz, 1 H), 6.79 – 6.96 (m, 2 H), 3.38 – 3.44 (m, 4 H), 3.36 (s, 3 H),

3.33 (s, 3 H), 2.92 – 3.04 (m, 4 H), 2.39 (s, 3 H); LCMS RT = 5.07 min, m/z 429.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₁H₂₅N₄O₄S [M+H⁺] 429.1591, found 429.1592.

6-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)benzo[d]oxazol-2(3H)-one (20)—

The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.14 (br. s., 1 H), 7.70 – 7.78 (m, 2 H), 7.63 (d, *J*=1.4 Hz, 1 H), 7.53 (dd, *J*=8.2, 1.6 Hz, 1 H), 7.26 (d, *J*=8.2 Hz, 1 H), 6.85 – 6.94 (m, 2 H), 3.35 – 3.45 (m, 4 H), 2.92 – 3.03 (m, 4 H), 2.39 (s, 3 H); LCMS RT = 5.07 min, m/z 402.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₁₉H₂₀N₃O₅S [M+H⁺] 402.1118, found 402.1130.

6-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-3-methylbenzo[d]oxazol-2(3H)-one (21)—

The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.71 – 7.76 (m, 2 H), 7.69 (d, *J*=1.4 Hz, 1 H), 7.62 (dd, *J*=8.3, 1.7 Hz, 1 H), 7.45 (d, *J*=8.0 Hz, 1 H), 6.78 – 6.95 (m, 2 H), 3.36 – 3.45 (m, 4 H), 3.33 (s, 3 H), 2.92 – 3.04 (m, 4 H), 2.39 (s, 3 H); LCMS RT = 5.22 min, m/z 416.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₂N₃O₅S [M+H⁺] 416.1275, found 416.1284.

5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one (22)—The title compound was prepared according to general protocol B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.88 (s, 1 H), 7.67 – 7.89 (m, 3 H), 6.79 – 7.08 (m, 3 H), 3.57 (s, 2 H), 3.36 – 3.46 (m, 4 H), 3.19 – 3.27 (m, 4 H), 2.43 (s, 3 H); LCMS RT = 4.92 min, m/z 434.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₁ClN₃O₄S [M+H⁺] 434.0936, found 434.0942.

5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-3,3-dichloroindolin-2-one (23)—

The title compound was prepared according to general protocol B. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 11.86 (s, 1 H), 7.95 (d, *J*=1.8 Hz, 1 H), 7.83 (dd, *J*=8.4, 2.0 Hz, 1 H), 7.73 – 7.80 (m, 2 H), 7.20 (d, *J*=8.4 Hz, 1 H), 6.90 – 6.98 (m, 2 H), 3.38 – 3.48 (m, 4 H), 2.99 – 3.08 (m, 4 H), 2.42 (s, 3 H); LCMS RT = 5.57 min, m/z 468.0 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₀Cl₂N₃O₄S [M+H⁺] 468.0546, found 468.0547.

6-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)isobenzofuran-1(3H)-one (24)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.11 (dd, *J*=8.0, 1.6 Hz, 1 H), 8.05 (d, *J*=1.0 Hz, 1 H), 7.94 (dd, *J*=8.1, 0.7 Hz, 1 H), 7.69 – 7.77 (m, 2 H), 6.85 – 6.95 (m, 2 H), 5.48 (s, 2 H), 3.36 – 3.46 (m, 4 H), 2.99 – 3.10 (m, 4 H), 2.39 (s, 3 H); LCMS RT = 5.12 min, m/z 401.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₁N₂O₅S [M+H⁺] 401.1166, found 401.1177.

6-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-3,4-dihydroquinolin-2(1H)-one (25)—

The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.46 (s, 1 H), 7.67 – 7.79 (m, 2 H), 7.54 (d, *J*=2.0 Hz, 1 H), 7.51 (dd, *J*=8.4, 2.2 Hz, 1 H), 7.00 (d, *J*=8.4 Hz, 1 H), 6.86 – 6.95 (m, 2 H), 3.34 – 3.46 (m, 4 H), 2.89 – 3.03 (m, 6 H), 2.40 (s, 3 H) (2 protons were hidden under DMSO-*d*₆ peaks); LCMS RT = 4.91 min, m/z 414.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₁H₂₄N₃O₄S [M+H⁺] 414.1482, found 414.1491.

7-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-4,5-dihydro-1H-

benzo[b]azepin-2(3H)-one (26)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.88 (s, 1 H), 7.70 – 7.78 (m, 2 H), 7.63 (d, *J*=2.3 Hz, 1 H), 7.58 (dd, *J*=8.3, 2.2 Hz, 1 H), 7.13 (d, *J*=8.2 Hz, 1 H), 6.85 – 6.95 (m, 2 H), 3.33 – 3.46 (m, 4 H), 2.93 – 3.05 (m, 4 H), 2.75 (t, *J*=6.8 Hz, 2 H), 2.40 (s, 3 H), 2.03 – 2.22 (m, 4 H); LCMS RT = 4.93 min, m/z 428.2 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₂H₂₆N₃O₄S [M+H⁺] 428.1639, found 428.1644.

N-(4-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)phenyl)acetamide (27)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.34 (s, 1 H), 7.76 – 7.82 (m, 2 H), 7.71 – 7.76 (m, 2 H), 7.61 – 7.69 (m, 2 H), 6.87 – 6.94 (m, 2 H), 3.35 – 3.43 (m, 4 H), 2.90 – 2.99 (m, 4 H), 2.40 (s, 3 H), 2.04 (s, 3 H); LCMS RT = 5.04 min, m/z 402.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₄N₃O₄S [M+H⁺] 402.1482, found 402.1485.

1-(4-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)phenyl)pyrrolidin-2-one (28)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.87 – 7.97 (m, 2 H), 7.67 – 7.77 (m, 4 H), 6.83 – 6.95 (m, 2 H), 3.84 (t, *J*=7.0 Hz, 2 H), 3.36 – 3.46 (m, 4 H), 2.89 – 2.99 (m, 4 H), 2.50 (t, *J*=8.1 Hz, 2 H), 2.39 (s, 3 H), 2.03 (ddd, *J*=15.1, 7.5, 7.3 Hz, 2 H); LCMS RT = 5.22 min, m/z 428.2 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₂H₂₆N₃O₄S [M+H⁺] 428.1639, found 428.1644.

1-(4-(4-(1-Acetyl-2-methylindolin-5-ylsulfonyl)piperazin-1-yl)phenyl)ethanone (29)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.11 (br. s., 1 H), 7.67 – 7.78 (m, 2 H), 7.47 – 7.63 (m, 2 H), 6.78 – 6.96 (m, 2 H), 4.51 – 4.76 (m, 1 H), 3.32 – 3.46 (m, 5 H), 2.88 – 3.03 (m, 4 H), 2.73 (d, *J*=16.8 Hz, 1 H), 2.40 (s, 3 H), 2.23 (s, 3 H), 1.18 (d, *J*=6.5 Hz, 3 H); LCMS RT = 5.38 min, m/z 442.2 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₃H₂₈N₃O₄S [M+H⁺] 442.1795, found 442.1797.

1-(4-(4-(1-Acetyl-1,2,3,4-tetrahydroquinolin-6-ylsulfonyl)piperazin-1-yl)phenyl)ethanone (30)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.80 – 7.87 (m, 1 H), 7.70 – 7.77 (m, 2 H), 7.52 (d, *J*=2.0 Hz, 1 H), 7.48 (dd, *J*=8.6, 2.3 Hz, 1 H), 6.86 – 6.95 (m, 2 H), 3.62 – 3.72 (m, 2 H), 3.36 – 3.44 (m, 4 H), 2.92 – 3.01 (m, 4 H), 2.78 (t, *J*=6.5 Hz, 2 H), 2.40 (s, 3 H), 2.18 (s, 3 H), 1.85 (dq, *J*=6.6, 6.3 Hz, 2 H); LCMS RT = 5.27 min, m/z 442.2 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₃H₂₈N₃O₄S [M+H⁺] 442.1795, found 442.1807.

7-(4-(4-acetylphenyl)piperazin-1-ylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (31)—The title compound was prepared according to general protocol C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.88 (s, 1 H), 7.71 – 7.78 (m, 2 H), 7.25 – 7.30 (m, 1 H), 7.23 – 7.25 (m, 1 H), 7.13 (d, *J*=8.4 Hz, 1 H), 6.85 – 6.94 (m, 2 H), 4.67 (s, 2 H), 3.37 – 3.46 (m, 4 H), 2.91 – 3.00 (m, 4 H), 2.40 (s, 3 H); LCMS RT = 4.94 min, m/z 416.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₀H₂₂N₃O₅S [M+H⁺] 416.1275, found 416.1281.

5-(4-(4-Acetylphenyl)piperazine-1-carbonyl)indolin-2-one (32)—The title compound was prepared according to general protocol D. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.55 (s, 1 H), 7.70 – 7.88 (m, 2 H), 7.23 – 7.40 (m, 2 H), 6.98 (d, *J*=9.2 Hz, 2 H), 6.85 (d, *J*=8.0 Hz, 1 H), 3.63 (br. s., 4 H), 3.51 (s, 2 H), 3.37 – 3.46 (m, 4 H), 2.45 (s, 3 H); LCMS RT = 4.14 min, m/z 364.1 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₁H₂₂N₃O₃S [M+H⁺] 364.1656, found 364.1661.

6-(4-(4-Acetylphenyl)piperazine-1-carbonyl)-3,4-dihydroquinolin-2(1H)-one (33)—The title compound was prepared according to general protocol D. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.22 (s, 1 H), 7.69 – 7.88 (m, 2 H), 7.26 (d, *J*=1.8 Hz, 1 H), 7.22 (dd, *J*=8.0, 2.0 Hz, 1 H), 6.90 – 6.98 (m, 2 H), 6.86 (d, *J*=8.2 Hz, 1 H), 3.60 (br. s., 4 H), 3.51 (br. s., 4 H), 2.88 (t, *J*=7.5 Hz, 2 H), 2.44 – 2.45 (m, 1 H), 2.40 – 2.43 (m, 4 H); LCMS RT = 4.30 min, m/z 378.2 [M+H⁺]; HRMS (ESI) m/z calcd. for C₂₂H₂₄N₃O₃S [M+H⁺] 378.1812, found 378.1815.

N-(4-(4-Acetylpiperazin-1-yl)phenyl)-2-oxoindoline-5-sulfonamide (34)—A

solution of 1-(4-(4-aminophenyl)piperazin-1-yl)ethanone (76.0 mg, 0.345 mmol), triethylamine (0.096 mL, 0.691 mmol) in DMF (3.00 mL) was treated at 0 °C with 2-oxoindoline-5-sulfonyl chloride (80.0 mg, 0.345 mmol). The reaction mixture was warmed to room temperature and stirred overnight. The crude mixture was filtered and purified by preparative HPLC to give the final product. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.72 (s, 1 H), 9.70 (s, 1 H), 7.51 (dd, *J*=4.0, 2.6 Hz, 2 H), 6.89 – 6.96 (m, 2 H), 6.84 – 6.89 (m, 1 H), 6.77 – 6.84 (m, 2 H), 3.53 (s, 6 H), 2.93 – 3.08 (m, 4 H), 2.00 (s, 3 H); LCMS RT = 3.55 min, *m/z* 415.1 [M+H⁺]; HRMS (ESI) *m/z* calcd. for C₂₀H₂₃N₄O₄S [M+H⁺] 415.1435, found 415.1448.

General Biological Experiments—The recombinant wild type enzyme Myozyme® (αglucosidase alfa), clinically approved for ERT, was obtained from Genzyme Corporation (Cambridge, MA). Patients' spleens were obtained from splenectomies with informed consent under an NIH-IRB approved clinical protocol # 86HG0096. Control spleens were obtained under the same NIH protocol #. 4-methylumbelliferyl-α-*D*-glucopyranoside (4MU-α-glc), resorufin α-*D*-glucopyranoside (res-α-glc), sodium taurocholate, and the buffer components were purchased from Sigma-Aldrich (St. Louis, MO). 1-Deoxynojirimycin (DNJ) was purchased from Tocris Bioscience (Minneapolis, MN). The human spleen tissue was homogenized using a food blender at the maximal speed for 5 minutes, followed by 10 passes in a motor-driven 50 mL glass-Teflon homogenizer. The homogenate was centrifuged at 1000×g for 10 minutes. The supernatant was then filtered using a 40 μm filter and aliquots of resultant spleen homogenate were frozen at –80 °C until use. The assay buffer was composed of 50 mM citric acid titrated with K₂PO₄ to make different pH solutions, and 0.01% Tween-20. The spleen homogenate assays used buffer at pH = 5, assays with recombinant wild type enzyme used buffer at pH = 5.9.

Enzyme Assay in 1,536-Well Plate Format—In black 1,536-well plates, a BioRAPTR FRD™ Microfluidic Workstation (Beckman Coulter, Inc. Fullerton, CA) was used to dispense 2 μL of the enzyme solutions into 1,536-well plates, and an automated pin-tool station (Kalypsys, San Diego, CA) was used to transfer 23 nL/well of compound to the assay plate. After 5 minutes incubation at room temperature, the enzyme reaction was initiated by the addition of 2 μL/well substrate. After 45 minutes incubation at 37 °C, the reaction was terminated by the addition of 2 μL/well stop solution. The fluorescence was then measured in the Viewlux, a CCD-based plate reader (Perkin Elmer, Waltham, MA), with a 365 nm excitation and 440 nm emission for the blue substrate, and 573 nm excitation and 610 nm emission for the red substrate. 27 μg/well of spleen homogenate was used as the enzyme solution. The final concentrations of the blue substrate and red substrate were 1 μM and 15 μM, respectively.

Thermo-denaturation Experiment—This assay measures the effect of compounds on the melting temperature (*T*_m) of the recombinant wild type GAA. The protocol was developed based on a previously reported general guideline.²² A mixture of GAA and SYPRO Orange (5000× stock concentration, Invitrogen, Carlsbad, CA) was delivered to a 384-well full-skirted white polypropylene plate (Roche Applied Science, Indianapolis, IN) with a final concentration of 1 μM and 5×, respectively. GAA and SYPRO Orange were diluted in 50 mM citrate acid buffer at pH = 5.0 supplemented with 100 mM KCl, 10 mM NaCl and 1 mM MgCl₂. A 6-point DMSO dilution series was made separately in a 384-well polypropylene plate (Thermo Fisher Scientific, Hudson, NH) for all analogs, whose final concentrations ranged from 0.82 – 200 μM. Half a microliter of each dilution point of each compound was transferred to the aforementioned GAA-SYPRO Orange mixture, with a final DMSO concentration of 2%. DMSO alone was also transferred to the assay plate for

each dilution series as a control sample. The plate was immediately centrifuged at 1,000 rpm for 10 second and subsequently sealed with sealing foils (Roche Applied Science). The plate was then heated using a LightCycler® 480 Instrument II (Roche Applied Science) from 20 to 95 °C at a ramping rate of 4.8 °C/s. SYPRO Orange fluorescence was monitored by a CCD camera using excitation and emission wavelengths of 498 and 580 nm, respectively. T_m was calculated through the LightCycler® 480 II Software.

Microscale Thermophoresis—GAA was labeled with a fluorescent dye NT-495 (NanoTemper Technologies) and the final concentration of the protein applied in equilibrium binding experiments was ~ 50 nM. A 16-point titration series of selected compounds was prepared in DMSO and was further transferred to protein solutions in a buffer containing 50 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl₂, pH = 7.5. The final concentrations of the compounds ranged from 250 μM to 7.63 nM, with the DMSO final concentration controlled at 2.5%. Samples were filled into Monolith NT™ standard treated capillaries (NanoTemper Technologies) after a room temperature incubation of 15 minutes. Capillary scan was performed on a NanoTemper Monolith NT.115 instrument, and thermophoresis was successively measured in each capillary. Measurement took place at room temperature with an 80% IR laser power, and the blue LED power set at 100%. Specifically, a laser-on time of 30 seconds and a laser-off time of 5 seconds were applied at the indicated IR-laser power. Data normalization and curve fitting were performed using GraphPad Prism 5.

Cells, Plasmids and Electroporation—Wild type fibroblasts and HEK cells were purchased from ATCC (Manassas, VA). Electroporation of the HEK cells with pCMV6XL6-GAA plasmid (Origene, Rockville, MD) was performed in a Nucleofector electroporator, according to the manufacturer's guidelines (Lonza, Walkersville, MD). Briefly, a mixture of 100 μL Nucleofector solution and 2 μg plasmid DNA was added to approximately 700,000 HEK cells, electroporation was performed with the Q_001 Nucleofector program. For our translocation experiments besides wt we used three Pompe fibroblast cell lines isolated from patients and with low passage number with the following mutations: Cell line F3248 heterozygous for: p.Y455C/p.G638W Cell line F0833 heterozygous for: p.L169P/p.D489N Cell line F2845 has a splice site mutation in one allele: c.IVS1-13T>G and p.G638W on the other one.

Western Blot Analysis—Equivalent amounts of total protein, as determined by BCA assay (Pierce Biotechnology, Rockford, IL), from HEK cells or fibroblasts were loaded onto 4–12 % Tris-Glycine gels. After blotting (iBlot PVDF, Invitrogen, CA), the PVDF membrane was blocked in Phosphate-buffered saline (PBS) containing 0.1% Tween-20 (Sigma) and 5% fat-free milk for 1 hour at room temperature. The blocked membrane was probed with a mouse monoclonal antibody against human GAA (Abnova, Walnut, CA), followed by incubation with HRP-labeled secondary anti-mouse antibody (Amersham Biosciences, Piscataway, NJ). The antigen-antibody complexes were detected with an Enhanced Chemiluminescence (ECL) kit (Amersham Biosciences). Alpha-Tubulin was used as the internal control for normalization.

Immunocytochemistry and Laser Scanning Confocal Microscopy—Wild type primary dermal human fibroblasts (ATCC) and primary Pompe fibroblasts were seeded in Lab-Tek 4 chamber slides (Fisher Scientific, Pittsburgh, PA). After chemical compound treatment for five or six days, fibroblasts were fixed in 3% paraformaldehyde. The cells were permeabilized with 0.1 % Triton-X for 10 min. and blocked in PBS containing 0.1% saponin, 100 μM glycine, 0.1% BSA and 2% donkey serum followed by incubation with mouse monoclonal anti-GAA (Abnova, Walnut, CA) or goat polyclonal anti-cathepsin D

(R&D Systems, Minneapolis, MN). The cells were washed and incubated with secondary donkey anti-mouse or anti-goat antibodies conjugated to ALEXA-488 or ALEXA-555, respectively (Invitrogen), washed again, and mounted in VectaShield with DAPI (Vector Laboratories, Burlingame, CA). Cells were imaged with a Zeiss 510 META confocal laser-scanning microscope (Carl Zeiss, Microimaging Inc., Germany) using an Argon (458, 477, 488, 514 nm) 30 mW laser, a HeNe (543 nm) 1 mW laser, and a laser diode (405 nm). Images were acquired using a Plan-Apochromat 63x/1.4 Oil, a Plan NeoFluar 40X/1.3 oil DIC objective, or a Plan-Apochromat 20x/0.15. Images were taken at the same laser settings.

Specific activity measurement

GAA activity in WT and Pompe fibroblasts was measured similar to the method used by Flanagan et al., 2009. Briefly, for each cell line cells were seeded in 3 black clear flat bottom 96-well plates (Perkin-Elmer, Waltham, MA) at 5,000 cells/well. Inhibitors (DNJ) were added (50nM to 503M), and the cells were incubated for 5 days with compounds; the media and compounds were changed on day 3. 1 plate of each cell line was assayed immediately while for 2 plates of each cell line, fibroblasts were washed with PBS and fresh medium without compounds was added (18 hour and 40 hour wash out). 30 μ L of assay buffer (30mM sodium citrate, 40mM sodium phosphate dibasic, 3mM 4MUG (Sigma), 33M Acarbose (Sigma), pH 4.0) was added (no wash out) and plates were incubated for 2 hours at 37C and 30 μ L of stop solution (1M NaOH, 1M glucine, pH 10) was added; a Victor plate reader (Perkin-Elmer) was used to measure fluorescence signal. Fluorescence counts from fibroblast assay buffer + stop solution (background counts) were subtracted from the cell samples and the relative GAA activity was calculated. Measurements were done in triplicate for each sample and the average GAA activity $\pm$ SD is reported.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank William Leister, Jim Bougie, Chris Leclair, Thomas Daniel, Heather Baker, Paul Shinn, and Danielle van Leer for assistance with compounds purification, HRMS analysis and compounds management. We also thank Ms. Allison Mandich and Ms. Mercedes Taylor for critical proofreading of the manuscript. This research was supported by the Molecular Libraries Initiative of the NIH Roadmap for Medical Research (U54MH084681) and the Intramural Research Program of the National Human Genome Research Institute and National Center for Advancing Translational Sciences, National Institutes of Health.

ABBREVIATIONS USED

LSDs	lysosomal storage diseases
GAA	acid alpha glucosidase
ER	endoplasmic reticulum
ERAD	endoplasmic reticulum-associated protein degradation
ERT	Enzyme replacement therapy
AMDE	absorption, distribution, metabolism, and excretion
BBB	Blood-Brain-Barrier
LAMP-2	lysosomal-associated membrane protein 2
HTS	high throughput screening

ML-SMR	Molecular Libraries-Small Molecule Repository
DNJ	1-deoxynojirimycin
FDA	U.S. Food and Drug Administration
DIBAL	diisobutylaluminium hydride
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
SAR	structure-activity relationship
NADPH	nicotinamide adenine dinucleotide phosphate
TLC	thin layer chromatography
HPLC	high performance liquid chromatography
DMF	dimethylformamide
DMAP	4-dimethylaminopyridine
MST	microscale thermophoresis

References

1. Smid BE, Aerts JMFG, Boot RG, Linthorst GE, Hollak CEM. Pharmacological small molecules for the treatment of lysosomal storage disorders. *Expert Opin Invest Drugs*. 2010; 19:1367–1379.
2. Hirschhorn, R.; Reuser, AJJ. Glycogen storage disease type II: acid α -glucosidase (acid maltase) deficiency. In: Valle, D., editor. *The metabolic and molecular bases of inherited disease*. Vol. Chapter 135. McGraw-Hill; New York: 2001.
3. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcibes P, Raben N, Plotz P. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. *Am J Med Genet*. 1998; 79:69–72. [PubMed: 9738873]
4. (a) <http://www.hgmd.cf.ac.uk>; Raben N, Plotz P, Byrne BJ. Acid α -glucosidase deficiency (glycogenosis type II, Pompe disease). *Curr Mol Med*. 2002; 2:145–166. [PubMed: 11949932]
5. (a) <http://www.myozyme.com/>; Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van dPA, Clancy JP, Parini R, Morin G, Beck M, De IGGS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant human acid α -glucosidase: Major clinical benefits in infantile-onset Pompe disease. *Neurology*. 2007; 68:99–109. [PubMed: 17151339]
6. <http://www.rxlist.com/myozyme-drug.htm>.
7. <http://en.wikipedia.org/wiki/Myozyme>.
8. Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease Yin and Yang of enzyme inhibitors. *FEBS J*. 2007; 274:4962–4971. [PubMed: 17894781]
9. (a) Hermans MMP, Van LD, Kroos MA, Beesley CE, Van dPAT, Sakuraba H, Wevers R, Kleijer W, Michelakakis H, Kirk EP, Fletcher J, Bosshard N, Basel-Vanagaite L, Besley G, Reuser AJJ. Twenty-two novel mutations in the lysosomal α -glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. *Hum Mutat*. 2004; 23:47–56. [PubMed: 14695532] (b) Montalvo ALE, Cariati R, Deganuto M, Guerci V, Garcia R, Ciana G, Bembi B, Pittis MG. Glycogenosis type II: identification and expression of three novel mutations in the acid α -glucosidase gene causing the infantile form of the disease. *Mol Genet Metab*. 2004; 81:203–208. [PubMed: 14972326] (c) Reuser AJJ, Kroos M, Oude ERPJ, Tager JM. Defects in synthesis, phosphorylation, and maturation of acid α -glucosidase in glycogenosis type II. *J Biol Chem*. 1985; 260:8336–8341. [PubMed: 3159730] (d) Reuser AJJ, Kroos M, Willemsen R, Swallow D, Tager JM, Galjaard H. Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid α -glucosidase in mutant fibroblasts. *J Clin Invest*. 1987; 79:1689–1699. [PubMed: 3108320]

10. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. *Hum Genet.* 2007; 121:1–22. [PubMed: 17089160]
11. (a) Asano N. Glycosidase inhibitors: update and perspectives on practical use. *Glycobiology.* 2003; 13:93R–104R. (b) Yoshimizu M, Tajima Y, Matsuzawa F, Aikawa S-i, Iwamoto K, Kobayashi T, Edmunds T, Fujishima K, Tsuji D, Itoh K, Ikekita M, Kawashima I, Sugawara K, Ohyanagi N, Suzuki T, Togawa T, Ohno K, Sakuraba H. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid [α]-glucosidase (alglucosidase alfa): Insight into the complex formation mechanism. *Clin Chim Acta.* 2008; 391:68–73. [PubMed: 18328816]
12. Fan JQ. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. *Biol Chem.* 2008; 389:1–11. [PubMed: 18095864] (b) http://en.wikipedia.org/wiki/Alpha-glucosidase_inhibitor
13. (a) Butters TD, Dwek RA, Platt FM. Therapeutic applications of imino sugars in lysosomal storage disorders. *Curr Top Med Chem.* 2003; 3:561–574. [PubMed: 12570866] (b) Lieberman RL, D'aquino JA, Ringe D, Petsko GA. Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability. *Biochemistry.* 2009; 48:4816–4827. [PubMed: 19374450]
14. (a) Flanagan JJ, Rossi B, Tang K, Wu X, Mascioli K, Donaudy F, Tuzzi MR, Fontana F, Cubellis MV, Porto C, Benjamin E, Lockhart DJ, Valenzano KJ, Andria G, Parenti G, Do HV. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid α -glucosidase. *Hum Mutat.* 2009; 30:1683–1692. [PubMed: 19862843] (b) Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van dPAT, Reuser AJJ. Chemical chaperones improve transport and enhance stability of mutant α -glucosidases in glycogen storage disease type II. *Mol Genet Metab.* 2007; 90:49–57. [PubMed: 17095274] (c) Parenti G, Zuppaldi A, Pittis MG, Tuzzi MR, Annunziata I, Meroni G, Porto C, Donaudy F, Rossi B, Rossi M, Filocamo M, Donati A, Bembi B, Ballabio A, Andria G. Pharmacological Enhancement of Mutated α -Glucosidase Activity in Fibroblasts from Patients with Pompe Disease. *Mol Ther.* 2007; 15:508–514. [PubMed: 17213836]
15. Motabar O, Shi ZD, Goldin E, Liu K, Southall N, Sidransky E, Austin CP, Griffiths GL, Zheng W. A new resorufin-based α -glucosidase assay for high-throughput screening. *Anal Biochem.* 2009; 390:79–84. [PubMed: 19371716]
16. (a) John M, Wendeler M, Heller M, Sandhoff K, Kessler H. Characterization of Human Saposins by NMR Spectroscopy. *Biochemistry.* 2006; 45:5206–5216. [PubMed: 16618109] (b) Zwerschke W, Mannhardt B, Massimi P, Nauenburg S, Pim D, Nickel W, Banks L, Reuser AJ, Jansen-Durr P. Allosteric activation of acid α -glucosidase by the human papillomavirus E7 protein. *J Biol Chem.* 2000; 275:9534–9541. [PubMed: 10734102]
17. Marugan JJ, Zheng W, Motabar O, Southall N, Goldin E, Westbroek W, Stubblefield BK, Sidransky E, Aungst RA, Lea WA, Simeonov A, Leister W, Austin CP. Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity. *J Med Chem.* 2011; 54:1033–1058. [PubMed: 21250698]
18. (a) Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular Libraries Initiative. *Science.* 2004; 306:1138–1139. [PubMed: 15542455] (b) Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yassar A, Zheng W, Austin CP. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proc Natl Acad Sci U S A.* 2006; 103:11473–11478. [PubMed: 16864780]
19. Bouchikhi F, Anizon F, Moreau P. Synthesis and antiproliferative activities of isoindigo and azaisoindigo derivatives. *Eur J Med Chem.* 2008; 43:755–762. [PubMed: 17628214]
20. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H, Hui R, Marsden BD, Nordlund P, Sundstrom M, Weigelt J, Edwards AM. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. *Proc Natl Acad Sci U S A.* 2006; 103:15835–15840. [PubMed: 17035505]
21. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S. Molecular interaction studies using microscale thermophoresis. *Assay Drug Dev Technol.* 2011; 9:342–353. [PubMed: 21812660]

22. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. *Nat Protoc.* 2007; 2:2212–2221. [PubMed: 17853878]

Figure 1.
Known iminosugars as inhibitors of α -glucosidase.

Figure 2.
Hydrolytic reactions of the red and blue dyes.

Figure 3. (A) Chemical structure of compound **1** identified from qHTS. (B) The GAA inhibitory activity of compound **1** as demonstrated by the hydrolysis of red and blue substrates using isolated GAA enzyme or tissue homogenates.

Figure 4. Thermostabilization of GAA functional activity. Time indicates length of incubation at 66 °C. Ratio is the ratio of enzymatic activity after incubation at 66 °C compared to room temperature incubation. Black: DMSO (duplicated); Red: DNJ (2.5 μ M); Green: qHTS sample of compound **1** (50 μ M); Blue: re-synthesized compound **1** (50 μ M).

Figure 5.
Capacity of inhibitors at 50 μ M to maintain the function of GAA after incubation at 66 $^{\circ}$ C for 60 minutes.

Figure 6. (A). ΔT_m versus concentrations for analogs **1** and **22**. (B). Microscale thermophoresis study of analogs **1** and **22** with GAA.

Figure 7.

Evaluation of compound **22** in GAA translocation assays using wild type and Pompe fibroblasts. (A) Western blot analysis of protein extracts from HEK cells over-expressing GAA (lane 1), HEK cells (lane 2) and wild type primary fibroblasts (lane 3). Tubulin was used as a loading control. (B, a) DMSO-treated Primary wild type fibroblasts. (B, b) DMSO-treated primary wild type fibroblasts stained with mouse Alexa-488 and goat Alexa-555(red) as a negative staining control. (B, c, d) Primary wild type fibroblasts treated with 15 μM (c) and 5 μM (d) of compound **22** for 6 days. (C, a) DMSO-treated primary Pompe fibroblasts. (C, b) Pompe fibroblasts (F2845) treated with 5 μM of compound **22** for 5 days. All stainings were performed with the anti-GAA mouse monoclonal antibody (green) and the anti-Cathepsin D goat polyclonal antibody (red); a DAPI stain was performed to visualize the nucleus (blue). Scale bar = 20 μm (B) and 50 μm (C).

Figure 8.

Relative inhibition of GAA in WT (A) and Pompe F2845 fibroblasts (B) in a whole cell assay with treatment of compound **22** and compound **1** at pH 4 with no wash-out and after 18 and 40 hours wash out. Data points have been normalized to GAA activity in vehicle treated cells (100%)

Scheme 1.

Synthesis of analogs with modifications of phenylpiperazine moiety of the molecule.

Scheme 2.

Synthesis of analogs with modifications of indolinone ring or sulfonamide portion of the molecule.

Table 1

GAA inhibitory activity of analogs with modifications of the aromatic ring attached to piperazine moiety.

#	R ₁	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
1		0.75	0.94
2	H	inactive	inactive
3		11.87	14.94
4		23.69	18.82
5		1.88	2.37
6		inactive	inactive
7		2.91	3.26

#	R ₁	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
8		3.66	3.26
9		inactive	inactive
10		94.31	94.31
11		inactive	inactive
12		inactive	inactive
13		14.94	14.94
14		3.66	4.11

#	R_1	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
15		25.90	36.61
16		1.30	1.46
17		12.98	12.98

Table 2

GAA inhibitory activity of analogs with modifications of the indolinone ring.

#	R ₁	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
1		0.75	0.94
18		inactive	inactive
19		inactive	inactive
20		inactive	inactive
21		inactive	inactive
22		1.63	1.63
23		32.61	41.05

#	R ₁	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
24		inactive	inactive
25		inactive	inactive
26		inactive	inactive
27		inactive	inactive
28		inactive	inactive
29		inactive	inactive
30		inactive	inactive

#	R ₁	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
31		inactive	inactive

Table 3

GAA inhibitory activity of analogs with modifications of sulfonamide and piperazine moieties.

#	Structure	IC ₅₀ (μM) Blue Dye	IC ₅₀ (μM) Red Dye
1		0.75	0.94
32		inactive	inactive
33		inactive	inactive
34		inactive	inactive

Table 4

ADME profile of 5 selected analogs with IC_{50} less than 3.0 μM in the GAA inhibitory assay using blue dye.

#	Structure	IC_{50} (μM) Blue Dye	PBS aqueous solubility (μM)	Mouse liver microsomes $T_{1/2}$ (minute)	Caco-2 Permeability mean $P_{app} A \rightarrow B$ ($10^{-6} cm s^{-1}$)	Caco-2 Permeability mean $P_{app} B \rightarrow A$ ($10^{-6} cm s^{-1}$)
1		0.75	7.9	>60	14.6	27.1
5		1.88	37.3	>60	17.8	19.5
7		2.91	14.9	57	N/A	N/A
16		1.30	>150	>60	0.60	0.20
22		1.63	20.8	>60	54.30	30.90